Loading…
XTL Biopharmaceuticals Ltd. is projected to rise to $4.31 by 2027, a +48% move from its current price of $2.91. XTLB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.75 | $2.91 | $3.08 | 0.00% |
| Jul 14 | $2.69 | $2.91 | $3.15 | -0.01% |
| Jul 15 | $2.64 | $2.91 | $3.21 | -0.01% |
| Jul 16 | $2.60 | $2.91 | $3.26 | -0.02% |
| Jul 17 | $2.56 | $2.91 | $3.30 | -0.02% |
| Jul 18 | $2.53 | $2.91 | $3.34 | -0.02% |
| Jul 19 | $2.50 | $2.91 | $3.38 | -0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.50 | $2.91 | $3.38 | -0.03% |
| Week 2 | $2.35 | $2.91 | $3.60 | -0.06% |
| Week 3 | $2.24 | $2.91 | $3.77 | -0.08% |
| Week 4 | $2.15 | $2.91 | $3.93 | -0.11% |
| Week 5 | $2.08 | $2.91 | $4.07 | -0.14% |
| Week 6 | $2.01 | $2.91 | $4.20 | -0.17% |
| Week 7 | $1.95 | $2.90 | $4.32 | -0.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
XTL Biopharmaceuticals Ltd. is a biopharmaceutical company that engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel.
Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
The company was formerly Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
XTL Biopharmaceuticals Ltd. (XTLB) is a biotechnology stock with current price $2.90.
It has a market cap of $7.13M and is ranked 5213.
Forecasts place the near-term average price at $2.90 in 2026, with a path to higher levels in subsequent years; the 2030 average is $4.27 and the 2050 average is $12.81, while the 2050 maximum could reach $29.46.
The forecast shows 2026 sentiment NEUTRAL and later years bullish.
A major floor 44.2% below — a decisive break under it would weaken the trend.
The nearest floor, 29.2% below — buyers have tended to step in here.
The nearest ceiling, 7.9% above — a clean break opens room to run.
A major ceiling 34.0% above — clearing it would confirm fresh momentum.
Key XTLB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XTLB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.96 | Sell | $2.88 | Buy |
| MA 10 | $2.75 | Buy | $2.80 | Buy |
| MA 20 | $2.62 | Buy | $2.69 | Buy |
| MA 50 | $2.67 | Buy | $2.64 | Buy |
| MA 100 | $2.67 | Buy | $2.80 | Buy |
| MA 200 | $3.30 | Sell | $3.34 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.22 | Neutral |
| Stoch RSI (14) | 64.34 | Neutral |
| CCI (20) | 83.05 | Neutral |
| Williams %R (14) | -29.49 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 4.30 | Buy |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 70.51 | Neutral |
| TRIX (15) | 0.38 | Buy |
| Awesome (5,34) | 0.46 | Buy |
| Ultimate (7,14,28) | 57.79 | Neutral |
| Momentum (10) | 0.34 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 3.00 | Sell |
| ADX (14) | 13.71 | Neutral |
| ATR (14) | 0.14 | Info |
The 30-day technical picture is BULLISH, with RSI14 at 60.
SMA50 is $2.65 and SMA200 is $3.32.
Support is at $2.06 and resistance at $3.14. The thirtyDayRange runs from $1.95 to $4.32, and annualized volatility stands at 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.06 | $2.91 | $4.53 | 0% | Neutral | |
| $3.13 | $4.31 | $6.43 | +48% | Bullish | |
| $3.04 | $4.46 | $7.08 | +53% | Bullish | |
| $2.49 | $3.84 | $6.40 | +32% | Bullish | |
| $2.65 | $4.28 | $7.43 | +47% | Bullish | |
| $2.30 | $3.89 | $6.99 | +34% | Bullish | |
| $1.85 | $3.27 | $6.06 | +12% | Neutral | |
| $2.83 | $5.19 | $9.88 | +78% | Bullish | |
| $3.18 | $6.07 | $11.86 | +109% | Bullish | |
| $3.00 | $5.95 | $11.89 | +105% | Bullish | |
| $2.93 | $6.52 | $14.31 | +124% | Bullish | |
| $5.76 | $12.81 | $29.46 | +340% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.06 | $2.91 | $3.43 | +0.00% |
| August 2026 | $2.19 | $2.65 | $3.35 | -8.82% |
| September 2026 | $2.36 | $2.90 | $3.74 | +9.28% |
| October 2026 | $2.58 | $3.21 | $4.21 | +10.75% |
| November 2026 | $2.57 | $3.23 | $4.29 | +0.53% |
| December 2026 | $2.65 | $3.36 | $4.53 | +4.17% |
Click any year to see its month-by-month XTLB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The XTLB price prediction for 2026 points to an average of $2.91 (low $2.06, high $4.53) — a potential gain of 0% on today's $2.91. A consolidation phase looks the most probable path here.
In 2027, XTLB is projected to trade between $3.13 and $6.43, averaging $4.31 — a potential gain of +48% from today's $2.91. That is up +48% on the projected 2026 average. Momentum favours further upside here.
XTL Biopharmaceuticals Ltd.'s 2028 outlook centres on $4.46, within a $3.04 to $7.08 range. That is up +3% on the projected 2027 average. That marks a +53% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, XTLB could reach as high as $6.40, with a base case around $3.84 and support toward $2.49 — roughly +32% from $2.91. Momentum favours further upside here.
Expect XTLB to range from $2.65 to $7.43 through 2030. The $4.28 average target implies a +47% move from current prices. That is up +12% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The XTLB price prediction for 2031 points to an average of $3.89 (low $2.30, high $6.99) — a potential gain of +34% on today's $2.91. Momentum favours further upside here.
In 2032, XTLB is projected to trade between $1.85 and $6.06, averaging $3.27 — a potential gain of +12% from today's $2.91. That is -16% versus the projected 2031 average. A consolidation phase looks the most probable path here.
XTL Biopharmaceuticals Ltd.'s 2033 outlook centres on $5.19, within a $2.83 to $9.88 range. That is up +59% on the projected 2032 average. That marks a +78% change versus current levels. Momentum favours further upside here.
By 2034, XTLB could reach as high as $11.86, with a base case around $6.07 and support toward $3.18 — roughly +109% from $2.91. Buyers look set to stay in control over this stretch.
Expect XTLB to range from $3.00 to $11.89 through 2035. The $5.95 average target implies a +105% move from current prices. That is -2% versus the projected 2034 average. Momentum favours further upside here.
The XTLB price prediction for 2040 points to an average of $6.52 (low $2.93, high $14.31) — a potential gain of +124% on today's $2.91. Buyers look set to stay in control over this stretch.
In 2050, XTLB is projected to trade between $5.76 and $29.46, averaging $12.81 — a potential gain of +340% from today's $2.91. That is up +97% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in XTLB today (≈ 343.642612 XTLB) could be worth
$4,401.92
+$3,401.92 (+340%) by 2050 · US Dollar
Based on the average projected XTLB price of $12.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XTLBwould be worth at today's price.
$1,000 invested in XTLB on Jul 10, 2025 (≈ 164.473686 XTLB) would be worth
$478.62
-$521.38 (-52.1%) today · 0.48× · US Dollar
Based on a XTLB entry price of $6.08 vs. today's $2.91.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.7 | $1,077.78 | +7.8% |
| 1 month ago | $2.32 | $1,254.31 | +25.4% |
| 3 months ago | $2.37 | $1,227.85 | +22.8% |
| 6 months ago | $2.72 | $1,069.85 | +7.0% |
| 1 year ago | $6.08 | $478.62 | -52.1% |
| All time (5.0y) ago | $14 | $207.86 | -79.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XTLB forecast.
Our base-case forecast reaches $5.80 around 2034.
Implied market cap at $5.80: $14.25M
In the multi-year forecast, 2026 min $2.06, avg $2.90, max $4.55; ROI 0 and sentiment NEUTRAL.
Beyond 2026, the years show bullish sentiment with rising averages and ROIs: 2027 avg $4.30 (ROI 48.3%), 2028 avg $4.42 (ROI 52.6%), 2029 avg $3.84 (ROI 32.5%), 2030 avg $4.27 (ROI 47.2%), 2031 avg $3.85 (ROI 32.8%), 2032 avg $3.27 (ROI 12.7%), 2033 avg $5.18 (ROI 78.7%), 2034 avg $6.03 (ROI 108.1%), 2035 avg $5.93 (ROI 104.4%), 2040 avg $6.45 (ROI 122.5%), and 2050 avg $12.81 (ROI 341.6%).
The long horizon also shows a maximum of $29.46 in 2050 and a minimum of $5.76, indicating substantial upside if realized. The history of the forecast underscores bullish potential in later years, but these are estimates and not guarantees. The status of hCDR1 as a Phase II-ready asset provides a context for these projections while acknowledging inherent clinical and market risks.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $2.64, avg $4.27, max $7.41, ROI 47.2%, sentiment BULLISH.
Forecasts show a mix near term with 2026 Neutral but bullish sentiment in 2027–2050; avg prices rise from $2.90 in 2026 to $12.81 in 2050, with notable ROIs such as 47.2% in 2030, 108.1% in 2034, and 341.6% in 2050.
Yes—the forecast max reaches $11.78 in 2034 and $11.84 in 2035, exceeding $10; 2033 max is $9.87.
Current price is $2.90 and market cap is $7.13M.
RSI14 is 60; SMA50 is $2.65; SMA200 is $3.32; Support is $2.06 and Resistance is $3.14; thirty-day range is $1.95 to $4.32; annualized volatility is 100%.
XTL Biopharmaceuticals Ltd. Community Discussion
0Share your XTL Biopharmaceuticals Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.